Cartesian Therapeutics Stock Analysis

RNAC Stock   17.12  0.19  1.12%   
Cartesian Therapeutics is overvalued with Real Value of 9.17 and Target Price of 3.5. The main objective of Cartesian Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cartesian Therapeutics is worth, separate from its market price. There are two main types of Cartesian Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cartesian Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cartesian Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Cartesian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.

Cartesian Stock Analysis Notes

About 58.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 47.22. Cartesian Therapeutics had not issued any dividends in recent years. The entity had 1:30 split on the 5th of April 2024. To find out more about Cartesian Therapeutics contact Carsten Brunn at 617 923 1400 or learn more at https://www.cartesiantherapeutics.com.

Cartesian Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cartesian Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cartesian Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cartesian Therapeutics had very high historical volatility over the last 90 days
Cartesian Therapeutics was previously known as SELB Old and was traded on NASDAQ Exchange under the symbol SELB.
The company reported the previous year's revenue of 26 M. Net Loss for the year was (219.71 M) with profit before overhead, payroll, taxes, and interest of 38.4 M.
Cartesian Therapeutics currently holds about 106.44 M in cash with (51.16 M) of positive cash flow from operations.
Roughly 58.0% of the company outstanding shares are owned by corporate insiders
Latest headline from thelincolnianonline.com: Cartesian Therapeutics Buy Rating Reiterated at Needham Company LLC

Cartesian Therapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cartesian Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Cartesian Largest EPS Surprises

Earnings surprises can significantly impact Cartesian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-17
2023-06-30-0.08-0.070.0112 
2021-03-11
2020-12-31-0.12-0.14-0.0216 
2024-03-07
2023-12-31-0.04-0.07-0.0375 
View All Earnings Estimates

Cartesian Stock Institutional Investors

Shares
Nuveen Asset Management, Llc2024-06-30
34.8 K
Northern Trust Corp2024-06-30
30.9 K
Marshall Wace Asset Management Ltd2024-06-30
30 K
Sphera Funds Management Ltd.2024-06-30
25.1 K
Delphi Financial Group Inc2024-06-30
22 K
Bank Of New York Mellon Corp2024-06-30
19.9 K
Charles Schwab Investment Management Inc2024-06-30
19 K
Renaissance Technologies Corp2024-06-30
17.1 K
Lake Street Advisors Group, Llc2024-09-30
15.8 K
Fmr Inc2024-06-30
510.8 K
Blackrock Inc2024-06-30
407.6 K
Note, although Cartesian Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cartesian Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 430.27 M.

Cartesian Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(2.07)(1.96)
Return On Capital Employed(0.36)(0.38)
Return On Assets(0.72)(0.76)
Return On Equity 0.50  0.53 

Management Efficiency

Cartesian Therapeutics has return on total asset (ROA) of (0.1095) % which means that it has lost $0.1095 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (70.2926) %, meaning that it created substantial loss on money invested by shareholders. Cartesian Therapeutics' management efficiency ratios could be used to measure how well Cartesian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.53, whereas Return On Tangible Assets are projected to grow to (1.96). At present, Cartesian Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 225 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.2 M.
Last ReportedProjected for Next Year
Book Value Per Share(85.14)(80.88)
Tangible Book Value Per Share(123.58)(117.40)
Enterprise Value Over EBITDA(0.15)(0.16)
Price Book Value Ratio(0.23)(0.22)
Enterprise Value Multiple(0.15)(0.16)
Price Fair Value(0.23)(0.22)
Enterprise Value35.7 M33.9 M
Evaluating the management effectiveness of Cartesian Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Cartesian Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin
(45.41)
Beta
0.832
Return On Assets
(0.11)
Return On Equity
(70.29)

Technical Drivers

As of the 14th of November 2024, Cartesian Therapeutics shows the Mean Deviation of 4.79, risk adjusted performance of 0.0729, and Downside Deviation of 5.64. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cartesian Therapeutics, as well as the relationship between them.

Cartesian Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cartesian Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cartesian Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Cartesian Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cartesian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cartesian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cartesian Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Hoge Elizabeth over a month ago
Disposition of 45551 shares by Hoge Elizabeth of Cartesian Therapeutics subject to Rule 16b-3
 
Springer Timothy A over a month ago
Acquisition by Springer Timothy A of 20045 shares of Cartesian Therapeutics at 46.5 subject to Rule 16b-3
 
Barabe Timothy C over three months ago
Acquisition by Barabe Timothy C of 7500 shares of Cartesian Therapeutics at 12.7 subject to Rule 16b-3
 
Malik Kemal over three months ago
Insider Trading
 
Malik Kemal over three months ago
Acquisition by Malik Kemal of 5933 shares of Cartesian Therapeutics subject to Rule 16b-3
 
English Emily over six months ago
Disposition of tradable shares by English Emily of Cartesian Therapeutics subject to Rule 16b-3
 
English Emily over six months ago
Disposition of 23433 shares by English Emily of Cartesian Therapeutics at 19.656 subject to Rule 16b-3
 
Springer Timothy A over six months ago
Disposition of 1970443 shares by Springer Timothy A of Cartesian Therapeutics at 1.46 subject to Rule 16b-3
 
Springer Timothy A over six months ago
Acquisition by Springer Timothy A of 3200 shares of Cartesian Therapeutics at 0.5837 subject to Rule 16b-3
 
Springer Timothy A over six months ago
Acquisition by Springer Timothy A of 1200 shares of Cartesian Therapeutics at 0.6541 subject to Rule 16b-3
 
Springer Timothy A over six months ago
Acquisition by Springer Timothy A of 178000 shares of Cartesian Therapeutics subject to Rule 16b-3
 
Springer Timothy A over six months ago
Acquisition by Springer Timothy A of 24785 shares of Cartesian Therapeutics subject to Rule 16b-3

Cartesian Therapeutics Outstanding Bonds

Cartesian Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cartesian Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cartesian bonds can be classified according to their maturity, which is the date when Cartesian Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Cartesian Therapeutics Predictive Daily Indicators

Cartesian Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cartesian Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cartesian Therapeutics Corporate Filings

8K
7th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F3
15th of October 2024
An amendment to the original Schedule 13D filing
ViewVerify
F4
4th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
1st of October 2024
Other Reports
ViewVerify
F4
27th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
26th of September 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
23rd of September 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
20th of September 2024
Other Reports
ViewVerify

Cartesian Therapeutics Forecast Models

Cartesian Therapeutics' time-series forecasting models are one of many Cartesian Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cartesian Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Cartesian Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cartesian Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cartesian shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cartesian Therapeutics. By using and applying Cartesian Stock analysis, traders can create a robust methodology for identifying Cartesian entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(9.18)(9.64)
Operating Profit Margin(3.32)(3.49)
Net Loss(8.45)(8.87)
Gross Profit Margin 0.94  1.06 

Current Cartesian Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cartesian analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cartesian analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
3.5Strong Buy6Odds
Cartesian Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cartesian analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cartesian stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cartesian Therapeutics, talking to its executives and customers, or listening to Cartesian conference calls.
Cartesian Analyst Advice Details

Cartesian Stock Analysis Indicators

Cartesian Therapeutics stock analysis indicators help investors evaluate how Cartesian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cartesian Therapeutics shares will generate the highest return on investment. By understating and applying Cartesian Therapeutics stock analysis, traders can identify Cartesian Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow108 M
Common Stock Shares Outstanding5.2 M
Total Stockholder Equity-440.2 M
Tax Provision-19 M
Quarterly Earnings Growth Y O Y0.537
Property Plant And Equipment Net12.2 M
Cash And Short Term Investments76.9 M
Cash76.9 M
Accounts Payable3.1 M
Net Debt-66 M
50 Day M A18.9618
Total Current Liabilities68.2 M
Other Operating Expenses112.4 M
Non Current Assets Total214.3 M
Forward Price Earnings25.4453
Non Currrent Assets Other1.4 M
Stock Based Compensation22.5 M

Complementary Tools for Cartesian Stock analysis

When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account